CDXC - ChromaDex Corp Stock Price, Fair Value and News

$6.40-0.27 (-4.05%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CDXC Price Action

Last 7 days

-1.6%

Last 30 days

-6.9%

Last 90 days

-31.1%

Trailing 12 Months

-11.4%

CDXC RSI Chart

CDXC Valuation

Market Cap

510.8M

Price/Earnings (Trailing)

Price/Sales (Trailing)

4.1

EV/EBITDA

20.4

Price/Free Cashflow

23.86

CDXC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CDXC Fundamentals

CDXC Revenue

Revenue (TTM)

124.7M

Rev. Growth (Yr)

32.86%

Rev. Growth (Qtr)

9.22%

CDXC Earnings

Earnings (TTM)

20.4M

Earnings Growth (Yr)

143.77%

Earnings Growth (Qtr)

26.85%

CDXC Profitability

Operating Margin

63.89%

EBT Margin

17.04%

Return on Equity

28.91%

Return on Assets

20.82%

Free Cashflow Yield

4.19%

CDXC Investor Care

Shares Dilution (1Y)

4.48%

Diluted EPS (TTM)

0.25

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	107.9M	116.3M	124.7M	0
2024	83.2M	85.6M	91.7M	99.6M
2023	77.3M	80.9M	83.4M	83.6M
2022	70.0M	69.1M	68.8M	72.0M
2021	59.6M	62.0M	65.1M	67.4M
2020	50.6M	54.8M	56.9M	59.3M
2019	35.0M	38.3M	42.3M	46.3M
2018	24.4M	28.0M	30.0M	31.6M
2017	19.2M	16.0M	18.1M	21.2M
2016	22.6M	23.9M	21.6M	21.7M
2015	17.5M	19.7M	21.9M	22.0M
2014	10.9M	12.0M	13.5M	15.3M
2013	12.2M	12.2M	11.3M	10.2M
2012	7.4M	8.1M	9.9M	11.6M
2011	7.7M	7.8M	8.0M	8.1M
2010	0	0	0	7.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About ChromaDex Corp

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

CEO	Mr. Robert N. Fried
WEBSITE	chromadex.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	113

ChromaDex Corp Frequently Asked Questions

What is the ticker symbol for ChromaDex Corp? What does CDXC stand for in stocks?

CDXC is the stock ticker symbol of ChromaDex Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ChromaDex Corp (CDXC)?

As of Tue Dec 02 2025, market cap of ChromaDex Corp is 510.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDXC stock?

You can check CDXC's fair value in chart for subscribers.

Is ChromaDex Corp a good stock to buy?

The fair value guage provides a quick view whether CDXC is over valued or under valued. Whether ChromaDex Corp is cheap or expensive depends on the assumptions which impact ChromaDex Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDXC.

What is ChromaDex Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 02 2025, CDXC's PE ratio (Price to Earnings) is 25 and Price to Sales (PS) ratio is 4.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDXC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ChromaDex Corp's stock?

In the past 10 years, ChromaDex Corp has provided 0.058 (multiply by 100 for percentage) rate of return.